Neugeborenenscreening auf Sichelzellkrankheit in Deutschland

Die Sichelzellkrankheit (SCD) ist eine angeborene Blutkrankheit, die unerkannt mit einer signifikanten Frühmorbidität und -mortalität verbunden ist. Da die Diagnose schon bei Geburt mit einer hohen Zuverlässigkeit gestellt werden kann, hat der Gemeinsame Bundesausschuss (G-BA) die Erweiterung des Neugeborenenscreenings (NBS) um die SCD beschlossen. Es ist zu erwarten, dass die SCD eine der häufigsten Diagnosen im dann 18 Zielkrankheiten umfassenden deutschen NBS-Programm sein wird.

Publication History

Article published online:
04 November 2021

• Literatur

• 1 Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med 2017; 376: 1561-1573 DOI: 10.1056/NEJMra1510865. (PMID: 28423290)
• 2 Ballas SK, Lieff S, Benjamin LJ. et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010; 85: 6-13 DOI: 10.1002/ajh.21550. (PMID: 19902523)
• 3 Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21: 37-47 DOI: 10.1016/j.blre.2006.07.001. (PMID: 17084951)
• 4 Wiesenfeld SL. Sickle-cell trait in human biological and cultural evolution. Development of agriculture causing increased malaria is bound to gene-pool changes causing malaria reduction. Science 1967; 157: 1134-1140 DOI: 10.1126/science.157.3793.1134. (PMID: 6038684)
• 5 Piel FB, Patil AP, Howes RE. et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 2010; 1: 104 DOI: 10.1038/ncomms1104. (PMID: 21045822)
• 6 Piel FB, Patil AP, Howes RE. et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381: 142-151 DOI: 10.1016/S0140-6736(12)61229-X. (PMID: 23103089)
• 7 Piel FB, Tatem AJ, Huang Z. et al. Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health 2014; 2: e80-e89 DOI: 10.1016/S2214-109X(13)70150-5. (PMID: 24748392)
• 8 Lobitz S, Klein J, Brose A. et al. Newborn screening by tandem mass spectrometry confirms the high prevalence of sickle cell disease among German newborns. Ann Hematol 2019; 98: 47-53 DOI: 10.1007/s00277-018-3477-4. (PMID: 30132072)
• 9 Lobitz S, Frommel C, Brose A. et al. Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany. Eur J Hum Genet 2014; 22: 1051-1053 DOI: 10.1038/ejhg.2013.286. (PMID: 24398797)
• 10 Grosse R, Lukacs Z, Cobos PN. et al. The Prevalence of Sickle Cell Disease and Its Implication for Newborn Screening in Germany (Hamburg Metropolitan Area). Pediatr Blood Cancer 2016; 63: 168-170 DOI: 10.1002/pbc.25706.
• 11 Kunz JB, Awad S, Happich M. et al. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening. Ann Hematol 2016; 95: 397-402 DOI: 10.1007/s00277-015-2573-y. (PMID: 26658910)
• 12 Pattloch D. Sichelzellkrankheit unter Neugeborenen in Deutschland: Eine Studie an Routinedaten der AOK. Gesundheitswesen 2019; 81: 986-992 DOI: 10.1055/a-0719-5165. (PMID: 30332709)
• 13 Andermann A, Blancquaert I, Beauchamp S. et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317-319 DOI: 10.2471/blt.07.050112. (PMID: 18438522)
• 14 Ribeil JA, Hacein-Bey-Abina S, Payen E. et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017; 376: 848-855 DOI: 10.1056/NEJMoa1609677. (PMID: 28249145)
• 15 Osunkwo I, Manwani D, Kanter J. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol 2020; 11: 2040620720955000 DOI: 10.1177/2040620720955000. (PMID: 33062233)
• 16 Bernaudin F, Dalle JH, Bories D. et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica 2020; 105: 91-101 DOI: 10.3324/haematol.2018.213207. (PMID: 31097628)
• 17 Voskaridou E, Christoulas D, Bilalis A. et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115: 2354-2363 DOI: 10.1182/blood-2009-05-221333. (PMID: 19903897)
• 18 Ataga KI, Kutlar A, Kanter J. et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med 2017; 376: 429-439 DOI: 10.1056/NEJMoa1611770. (PMID: 27959701)
• 19 Streetly A, Sisodia R, Dick M. et al. Evaluation of newborn sickle cell screening programme in England: 2010–2016. Arch Dis Child 2018; 103: 648-653 DOI: 10.1136/archdischild-2017-313213. (PMID: 29104181)
• 20 Lobitz S, Telfer P, Cela E. et al. Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. Br J Haematol 2018; 183: 648-660 DOI: 10.1111/bjh.15600. (PMID: 30334577)